• Dicerna Pharmaceuticals
• 01 Nov, 2019

Dicerna Pharmaceuticals has signed a research collaboration and licensing agreement with Roche to create treatments for chronic hepatitis B virus (HBV) infection. The partnership will leverage Dicerna’s GalXC RNAi platform, designed to develop RNAi-based therapies that silence genes, which cause diseases in the liver and other organs. Initially, the companies will work to develop and commercialise Dicerna’s investigational drug, DCR-HBVS, worldwide.
Read more...